A new formulation of mometasone furoate (MF) for administration by dry powder inhaler (DPI) was evaluated for the treatment of asthma. A 12-week, double-blind, placebo-controlled dose-ranging study compared the efficacy and safety of three doses of MF DPI (100, 200 and 400 mcg b.i.d) with beclomethasone dipropionate (BDP) 168 mcg b.i.d. administered by metered dose inhaler in 365 adult or adolescent patients being treated with inhaled glucocorticoids. The mean change from baseline to endpoint (last treatment visit) for forced expiratory volume in 1 set (FEV1) was the primary efficacy variable. Secondary efficacy variables included other objective measures of pulmonary function [forced vital capacity (FVC), forced expiratory flow 25-75% (FEV25-75%, ) and peak expiratory flow rate (PEFR)] as well as subjective measures of therapeutic response (patients' daily evaluation of asthma symptoms and physicians' evaluatiori). At endpoint, all four active treatments were significantly more effective than placebo (P<O=Ol) in improving FEVl (MF DPI 5 to 7%, BDP 3%, placebo -6.6%) and all other measures of pulmonary function (FVC: MF DPI 4 to 5%, BDP 2%, placebo -4.7%; FEFz5-75%: MF DPI 6 to 18%, BDP 7.5%, placebo -9.5%; PEFR (AM): MF DPI 5 to lo%, BDP 5.7 %, placebo -7%). 
Introduction
Inhaled glucocorticoids are the most effective medication for the long-term control of mild, moderate or severe persistent asthma (l-3). Their potent anti-inflammatory activity is responsible for their therapeutic effects, which include control of asthma symptoms, improvement of pulmonary function, decrease in airway hyperresponsiveness and, possibly, prevention of airway wall remodeling (4) .
Although inhaled glucocorticoids are generally safe and well-tolerated, systemic effects have been observed with currently available agents, particularly at high doses (4) (5) (6) . Although the risk of systemic adverse effects with inhaled glucocorticoids is much lower than it is with their oral counterparts, the potential for systemic exposure is increased in patients who require long-term or high-dose inhaled glucocorticoids or who take concomitant glucocorticoid therapy for other conditions, such as allergic rhinitis. Thus, there is a therapeutic benefit from potent inhaled glucocorticoids with extremely low systemic bioavailability.
The efficacy of an inhaled glucocorticoid depends not only on the pharmacological activity of the drug molecule, but also on the ability of the inhaler device to deliver therapeutic doses to the sites of airway inflammation. Many of the currently available metered dose inhalers (MDTs) and dry powder inhalers (DPIs) demonstrate substantial variations in the proportion of the delivered dose that actually reaches the conducting airways (4) . Thus, a need also exists for improved delivery systems as well as formulations that are free of chlorofluorocarbons, which are being phased out in all manufactured products because of environmental concerns.
Mometasone furoate (MF) is a highly potent topical glucocorticoid that has been shown to be effective in controlling the symptoms of seasonal and perennial rhinitis with once-daily administration as an aqueous nasal spray (MFNS) (7) (8) (9) . Following intranasal administration, MF had negligible systemic bioavailability, and no HPA-axis suppression was reported with single doses up to 4000 mcg, which is 20 times the recommended daily dose of 200 mcg (10) . In studies comparing the in vitro effects of glucocorticoids in inhibiting cytokine production, histamine release and eosinophil survival, MF consistently ranked with fluticasone propionate as the most potent glucocorticoid, followed by beclomethasone, triamcinolone, budesonide, and betamethasone (11, 12) . MF was the most potent glucocorticoid analyzed in vitro for relative binding affinity for the glucocorticoid receptor and stimulation of receptormediated transactivation of gene expression (13) . MF has recently been formulated as a pure powderlactose mixture (one part mometasone furoate to 5.8 parts lactose) for administration by a novel breath-actuated DPI for the treatment of asthma. The present study was the first clinical trial to evaluate MF DPI for the treatment of moderate asthma in patients who were previously maintained on inhaled glucocorticoids.
This placebo-controlled study compared the efficacy and safety of twice-daily administration of three dosages of inhaled MF DPI (100 mcg, 200 mcg and 400 mcg) with MD1 beclomethasone dipropionate (BDP; 168 mcg) in adults and adolescents.
Methods

PATIENTS
Male and female patients, 12 years of age or older, who had a history of asthma for at least 6 months and had been using an inhaled glucocorticoid daily for at least 30 days, were eligible to participate in the study. For the 2 weeks prior to the screening visit, the patients must have been on a stable regimen of flunisolide, triamcinolone acetonide (TAA), beclomethasone dipropionate (BDP), or fluticasone propionate (FP). All patients were non-smokers or had discontinued smoking more than 6 months prior to screening. Certain medications that might interfere with the action of inhaled corticosteroids (e.g. corticosteroids by other routes, bronchodilators, cromolyn sodium, antihistamines and decongestants)
were restricted prior to the screening visit. At the screening visit, patients had to demonstrate reversibility of airway disease, which was defined as an increase in absolute forced expiratory volume in 1 s (FEVi) of 212% (with an absolute increase of 2200 ml) within 30 min after administration of two puffs of albuterol.
Protocol inclusion criteria also required that patients demonstrate at screening and at baseline (day 1, prior to initiation of treatment) FEVi values 2 60% -190% of predicted normal values. Before treatment assignments were unblinded, it was determined that two subjects included in this study did not meet this criterion (one with a FEVi of 101.6% and another with a FEVi of 99.6%). Therefore, these two subjects were not included in the efficacy-evaluable data subset of subjects (see Statistical Analysis). In addition, subjects who had no follow-up data beyond the baseline visit, or who received dosing for no more than 2 days were also excluded from this data set. All patients had clinically acceptable values for complete blood count, blood chemistry profile, urinalysis, standard 12-lead electrocardiograms (ECGs) and vital signs, and all were free of other clinically significant disease. Patients screened at five sites were required to have a baseline unstimulated plasma cortisol level 25 mcg dll ' and a level 2 18 mcg dl-' 30 min after stimulation with cosyntropin (Cortrosyna, Organon, Inc.), a synthetic form of adrenocorticotropic hormone (ACTH).
Patients were excluded for any of the following reasons: pre-menarche, pregnancy, or lactation; immunotherapy, unless on a stable maintenance; treatment with oral glucocorticoids for > 14 days in the 6 months before screening, methotrexate, cyclosporin, or gold within 3 months, or systemic steroids or another investigational drug in the month before screening; dependence upon daily use of nebulized B-agonists; the need for ventilator support in previous 5 years; hospitalization for asthma in the previous 3 months; requirement of > 12 puffs day-' of albuterol on 2 consecutive days between the screening and baseline visits; an upper or lower respiratory tract infection (viral or bacterial) in the 2 weeks prior to screening; or evidence of clinically significant oropharyngeal candidiasis. Women of child-bearing potential were required to use an acceptable method of birth control.
STUDY DESIGN
This double-blind, randomized, double-dummy doseranging study compared three doses of MF DPI to placebo and BDP MD1 and was conducted at 20 study centers in the U.S.A. Patients were randomized to one of the five treatment arms according to a computer-generated code. The protocol was approved by the institutional review board for each treatment centre, and written informed consent was obtained from each patient or from the parent or guardian of patients under 18 years of age. During a l-to 2-week screening period, each patient continued the use of the previously prescribed inhaled glucocorticoid and was provided with an albuterol inhaler to be used as needed.
At the baseline visit, spirometry was performed to measure FEVr, forced vital capacity (FVC), and forced expiratory flow between 25 and 75% of vital capacity (FEF2s-&. Eligible patients discontinued the use of their previous inhaled glucocorticoid and were randomly assigned to one of the following treatments twice daily: MF DPI 100, 200, or 400 mcg; BDP MD1 168 mcg; or placebo. In keeping with the double-blind study design, each patient received both a DPI and an MD1 inhalation device and was instructed to take one inhalation from the DPI followed by four inhalations from the MD1 every morning and evening approximately 12 h apart.
All patients completed a daily diary card documenting morning and evening peak expiratory flow rate (PEFR), asthma symptoms, number of albuterol inhalations, number of nocturnal awakenings for asthma symptoms requiring albuterol use, adverse events and the use of study drug and concomitant medications. Treatment visits occurred after 1, 2, 4, 8, and 12 weeks of treatment. An oropharyngeal exam was performed at each visit, cultures taken if appropriate and evidence of candidiasis was recorded as an adverse event.
EFFICACY ASSESSMENTS
The primary efficacy variable was the mean change from baseline to endpoint (the last available treatment visit) in FEVi. Secondary efficacy variables included mean changes from baseline in FVC, FEF2j-?s%: and PEFR; symptom scores; albuterol inhalation use; nocturnal awakenings due to asthma; and physician assessments of response to therapy. Severity of asthma symptoms (wheezing, difficulty breathing, and cough) was rated on a four-point scale (0 = none, 1 = noticeable, 2 = annoying, 3 =very uncomfortable). The physicians also rated wheezing on a four-point scale (0 =none, 1 =wheezing on forced expiration, 2=wheezing during tidal volume on expiration only, and 3 = wheezing during tidal volume on expiration and inspiration). The response to therapy was numerically evaluated from 1 to 5, as much improved (1) improved (2) no change (3), worse (4) or much worse (5), when compared with symptoms at baseline.
Time to worsening of asthma was recorded and was defined as the first occurrence of any of the following: 20% or greater decrease in FEVi from baseline; clinical asthma exacerbation requiring emergency treatment, hospital admission, or treatment with asthma medications in addition to those permitted in the protocol; 25% or greater decrease on 2 consecutive days in AM or PM peak flow from the mean baseline AM value; more than 12 puffs per day for 2 consecutive days of use of a rescue bronchodilator (albuterol); or more than two treatments with nebulized albuterol on 2 consecutive days.
SAFETY ASSESSMENTS
HPA-axis function was assessed in patients from five of the 20 treatment centers. At the screening visit and again at week 12, plasma cortisol concentrations were determined in blood samples drawn at 0800 hours (& 1 h), before cosyntropin stimulation with an intravenous injection of 0.25 mg cosyntropin. Post-cosyntropin plasma cortisol concentrations were determined 30 min after the injection.
All patients were monitored for adverse events and changes in vital signs, hematological and blood chemistry profiles, and ECG during the la-week double-blind treatment period. Concentrations of MF were measured in plasma samples collected on the last study day from the same patients who participated in cosyntropin stimulation tests before and 30 min after the last dose of MF, using a validated high-pressure liquid chromatography (HPLC) assay with tandem mass spectrometry detection (14) .
STATISTICAL ANALYSIS
With 60 subjects per treatment group there would be a 90% power (two-sided level of significance, CI = 0.05) to detect a clinically meaningful difference in the mean change from baseline in FEVi between any paired treatment groups. This test would detect mean treatment differences of 11% or more from baseline. The evaluation of endpoint results adjusted for the discontinuation of patients over time by including the data from the last available treatment visit for each patient.
The change from baseline in FEVi, as well as the secondary efficacy variables, were analysed using a two-way analysis of variance (ANOVA) that extracted sources of variation due to treatment and centre. Pairwise comparisons were based on least squares means from the ANOVA using a 5% significance level. If the test for non-decreasing response among the treatment groups was significant, each pairwise comparison was to be performed at the 0.05 (twosided) level of significance, with no adjustment for multiple comparisons. Plasma cortisol concentration data from the cosyntropin stimulation tests were also analysed by the ANOVA model described above.
Responses for both the primary and secondary variable were analysed initially using the entire population of treated subjects so that efficacy conclusions were not biased by a subset analysis. Since a small percentage (4%) of patients were found to be non-evaluable, according to the criteria determined prior to unblinding the study, an efficacyevaluable subset of patients was then used to confirm the results obtained for the primary efficacy variable. The results from this subset analysis supported the initial findings and showed that the data for these patients did not affect outcome.
Results
PATIENT POPULATIQN
A total of 36.5 subjects, 12-74 years old, were treated. Randomization resulted in comparable treatment groups at baseline with respect to demographics (Table 1) and asthma-related characteristics (Table 2) . Mean FEVi at baseline was comparable among the treatment groups and ranged from 74 to 78% of predicted value. The majority of patients (76%) completed the study. The most common reasons for discontinuation were treatment failure (13%) and adverse events (6%), but their distribution among the groups was not comparable. Only 7 or 8% of patients treated with any dose of MF DPI or with BDP discontinued due to treatment failure, compared with 38% of placebo-treated patients. Adverse events resulted in discontinuation of 5, 3 and 4% for patients treated with MF DPI 100, 200 and 400 mcg b.i.d., respectively, 8% of those treated with BDP and 11% given placebo. The specific adverse events are described below.
EVALUATION OF EFFICACY: FEVl
At endpoint, the differences in mean changes from baseline between each active treatment group and the placebo group were highly significant (PC 0.01) for each objective efficacy variable (Table 3) The mean change in FEVi from baseline, the primary efficacy variable, was significantly greater for each of the four active treatment groups than the placebo group (PcO.01) at endpoint ( Table 3 ). The improvement in FEV, was sustained over time for all active treatment groups, and this effect was particularly evident for the MF DPI 200 mcg b.i.d. treatment group (Fig. 1) . 1130 (10) 1313 (8) 1000 (4) 1111 (9) 1063 (8) FP, mean mcg day-' (n)
435 (9) 363 (10) 440 (7) 550 (5) 388 (8) At endpoint, FEVi had decreased by a mean of 6.6% in the placebo group but had increased by 4. Additional analyses evaluated the change in FEVt by severity of asthma in patients with a baseline FEVi < 75% of the predicted value and those with a baseline FEV, 275% of the predicted value. In both subsets, the trends for improvement in FEVi were similar to those for the entire patient population (Table 3 ). In general, response to active drug treatment was more pronounced in patients with more severe asthma but there was little difference between the two subsets in the response to placebo (Table 3) .
EVALUATION OF EFFICACY: OTHER MEASURES OF PULMONARY FUNCTION
Results of other assessments of pulmonary function supported the improvements in FEVi observed for the active treatment groups. The increase in FVC from baseline indicated that all doses of MF DPI were superior to placebo (P<O.Ol) ( (Table 3) Mean values for PEFR, measured each day before dosing by the patient and before the use of albuterol (if required), increased from baseline values throughout the 12 weeks of treatment and these increases were higher in the morning than in the evening for all active treatment groups and the placebo group (Fig. 2) . At endpoint, as at most treatment visits, the increases in morning and evening PEFR for each active treatment group (3.8-9~9~~) were significantly greater (PC 0.01) than the decreases for the placebo group (-3.9 to -7.0%) ( Table 3) . Again, the analysis showed that MF DPI 200 mcg b.i.d., which provided significantly better control than the 100 mcg b.i.d. dose (P<O.O2), was the optimal dose for improvement in PEFR.
TIME TO WORSENING OF ASTHMA
Kaplan-Meier estimates of time to worsening of asthma showed that all four active treatments were different from placebo, which had a median time to worsening of approximately 55 days (Fig. 3) . Because more than 80% of patients in each active treatment group had not met criteria for worsening at their last visit, median time to worsening could not be determined for these groups. This measure of efficacy confirmed that all doses of MF DPI were superior to placebo and consistent with improved control of asthma.
EVALUATION OF ASTHMA SIGNS AND SYMPTOMS
Because patients' asthma was generally well controlled at study entry, relatively few patients reported symptoms or had symptoms at baseline. Therefore, results of symptom evaluation should be interpreted with caution. For those who did have symptoms, evening symptoms were less pronounced but qualitatively similar to morning symptoms. Mean scores were significantly lower for all active treatment groups than for placebo at most treatment visits (P<O*OS, data not shown) and at endpoint (P<O.Ol, Table 3 ). Improvement of these symptoms was comparable among the MF DPI 200 and 400 mcg b.i.d. treatment groups and the BDP 168 mcg b.i.d. group and somewhat better than the improvement for the MF DPI 100 mcg b.i.d. treatment group.
Significant reductions in coughing for the active treatment groups compared to the placebo group were observed at endpoint (PcO.01, Table 3 ). There was little numerical difference among the three MF DPI groups in the reduction of coughing score, and no statistically significant differences were detected (PpO.05).
At baseline and throughout the 12 weeks of treatment, mean scores for the physicians' evaluation of wheezing were similar among the treatment groups, with few significant differences (data not shown). At endpoint, however, the scores for the three MF DPI treatment groups were significantly lower than that for the placebo group (P<O.O5, Table 3 
RESCUE MEDICATION USE AND NOCTURNAL AWAKENINGS
Several other parameters were evaluated as additional measures of the efficacy of MF DPI (Table 3) (P = 0.01; data not shown). At endpoint, the symptoms in 67% and 66% of patients treated with MF DPI 200 and 400 mcg b.i.d., respectively, were improved or much improved, as compared with only 20% of those given placebo (Fig. 4) .
Responses to MF DPI 100 mcg b.i.d. and BDP 168 mcg b.i.d. were comparable and also better than the response to placebo, with 56 and 5 1% of patients in the respective active treatment groups considered improved or much improved at endpoint. Similarly, symptoms in only l&15% of patients in any of the four active treatment groups worsened, as compared with 57% of patients in the placebo group.
Statistical analysis confirmed the difference between the numerical scores for the placebo group and all active treatment groups (P<O.O2), demonstrating a significantly better response by week 1 and at each subsequent treatment visit (P<O.O3, data not shown). As observed with the assessments of pulmonary function and asthma symptoms, the greatest responses to therapy were seen in the MF DPI 200 and 400 mcg b.i.d. treatment groups, but there was no statistical evidence of an additional benefit of the higher dose of MF DPI. 
EVALUATION OF SAFETY
Safety data showed that all doses of MF DPI were well tolerated. Treatment-related adverse events occurred in 18 28% of the patients in the MF DPI treatment groups, 21% of those in the BDP treatment group and 22% of patients in the placebo group (Table 4) . The most frequently reported were headache, oral candidiasis and pharyngitis.
Treatment-related headache was similar among groups (range: 3-5%). Oral candidiasis (415%) was reported more often for the MF DPI 400 mcg b.i.d. (15%) group than for the other dosage groups (l-6%).
Most adverse events were mild to moderate in intensity and none was life-threatening. In only three patients was a treatment-related adverse event considered severe. These were aggravated asthma in one patient in the MF DPI 200 mcg b.i.d. treatment group and one in the BDP 168 mcg b.i.d. treatment group, and aggravated wheezing and chest pain in one patient in the placebo group.
Treatment with MF DPI or BDP was interrupted in some patients because of an adverse event, but generally these were considered unrelated to treatment and there was no pattern of occurrence. Of the 23 patients who discontinued treatment due to adverse events, only four had adverse events considered possibly or probably treatmentrelated (two patients in the placebo group and one each in the MF DPI 100 mcg b. with MF DPI also had significantly fewer signs and symptoms of asthma, less albuterol use as rescue medication and fewer nocturnal awakenings. In addition, the physicians' evaluation of response to therapy showed that all doses of MF DPI were more effective than placebo for clinical improvement from baseline.
The increases in FEVi in the MF DPI treatment groups were both statistically and clinically significant. All patients had been maintained on inhaled glucocorticoids prior to enrollment and switched to one of the active treatment groups at baseline. Therefore, the increases in FEVi indicated not only a continuation of the effect of previous inhaled glucocorticoid therapy but also an improvement over that effect. This observation was supported by the improvements in the FVC and parameters of lower airway function, including FEF25-,s%, and morning and evening PEFR.
The results showed consistently that the 200 mcg b.i.d. dose of MF DPI was superior to the 100 mcg b.i.d. dose and that no additional benefit of the 400 mcg b.i.d. dose could be demonstrated. In addition, the efficacy of the MF DPI 100 mcg b.i.d. dose was similar to that of BDP 168 mcg b.i.d. This points to the sensitivity of the study design to demonstrate both the lower limit and the upper threshold of effective doses, since significant differences were found at endpoint in FEFzsm7sQh and PEFR with only a two-fold increase in dose, i.e. between the 100 and 200 mcg b.i.d. doses.
In contrast, dose-ranging studies of other inhaled glucocorticoids have failed to demonstrate significant differences in efficacy between adjacent dose levels, even with a four-fold or greater difference in dose (4). For example, three dose-ranging studies of fluticasone propionate, one comparing 25, 100 and 500 mcg b.i.d. and the other two comparing a narrower range of 50, 100 and 250 mcg b.i.d., show all doses more effective than placebo after 8 or 12 weeks of treatment, but no statistically significant differences among doses (15) (16) (17) . Another study found a significant difference (P< 0.05) between daily doses of 100 and 200 mcg of fluticasone propionate in response to methacholine challenge, but not in endpoint values for pulmonary function tests, total symptom scores, or rescue bronchodilator use after 8 weeks of therapy (18) . A crossover study comparing 400 and 1000 mcg BDP with 400 and 800 mcg BUD by aerosol inhalation failed to detect significant differences between the drugs or between the high or low doses of each drug (19) .
However, several reports have suggested that higher than usual doses of inhaled glucocorticoid may lead to significant improvement in patients with moderate or severe asthma or those with stable disease (20, 21) . The cosyntropin stimulation test assesses the response of the adrenal glands to stimulation and, thus, of HPA-axis function (22) . The present study found no evidence of clinically relevant HPA-axis suppression in any treatment group, as measured by response to cosyntropin stimulation. This lack of effect on cosyntropin stimulation of the HPA axis is consistent with studies with other inhaled glucocorticoids when employed at the low to mid range of clinically effective doses (4) .
All doses of MF DPI were well tolerated in this study, with most adverse events of mild or moderate intensity. The most common treatment-related adverse events were headache, oral candidiasis, and pharyngitis. Although oral candidiasis occurred in 15% of the MF DPI 400 mcg b.i.d. group, no patients discontinued treatment due to this adverse effect. Candidiasis is reported at similar rates in other studies using inhaled glucocorticoids to replace oral glucocorticoids (23, 24) . Considering the lack of additional efficacy benefit with the 400 mcg b.i.d. dose in this study, these findings further suggest that MF DPI 200 mcg b.i.d. was the optimal dose in these patients with moderate persistent asthma being treated with inhaled glucocorticoids. It is possible that patients with severe persistent asthma may have a higher optimal dose.
In summary, this 12-week study showed that inhaled mometasone furoate administered by dry powder inhaler in a dose range of 100400 mcg twice daily was significantly more effective than placebo for the treatment of moderate persistent asthma in adults and adolescents previously maintained on inhaled glucocorticoids. A dosage of 200 mcg twice daily provided significantly improved pulmonary function by the fourth day of treatment that was sustained for the duration of the study. This dosage also significantly reduced asthma symptoms, the need for rescue medication, and nocturnal awakenings due to asthma symptoms. MF DPI was also well tolerated, with no evidence of HPA-axis suppression.
